Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NCATS Opens Repurposing Project With 58 Compounds, 17 From Pfizer

Executive Summary

The National Institutes of Health’s National Center for Accelerating Translational Science has opened the pilot round of its compound repurposing effort with 58 drug candidates that will be made available to academic researchers. Half of the 58 have failed in previous studies for neurological indications, a recognized trouble spot for drug development.

You may also be interested in...

AstraZeneca Has Stake In Three Of Nine NCATS Research Projects

Nine NIH National Center for Advancing Translational Sciences research projects involving repurposed investigational drugs will be funded with a total of $12.7 million and cover eight disease areas. In addition to AstraZeneca, compounds provided by Pfizer, Sanofi, Lilly and Janssen will be studied.

NIH Royalties For Pfizer, AstraZeneca, Lilly Drugs Remain Open Question In Repurposing Initiative

With collaborative research agreement templates that include many of the details for a licensing agreement, royalties will be the major issue to be resolved if researchers develop new IP for one of the firm’s abandoned compounds.

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts